Celecoxib is a selective COX-2 inhibitor that inhibits the formation of prostaglandins resulting in anti-inflammatory, antipyretic, and analgesic effects. Unlike the non-selective non-steroidal anti-inflammatory drugs (NSAIDS) (e.g. ibuprofen and aceclofenac acid), it does not cause gastrointestinal upset such as gastritis.
It is used to treat the following conditions:
-
For the Management of acute pain
-
For pain and inflammation associated with Ankylosing spondylitis
-
For the relief of pain and inflammation in patients 2 years of age or older with Juvenile idiopathic arthritis
-
For the symptomatic treatment of Osteoarthritis
-
For the treatment of Primary dysmenorrhea
-
For inflammation and pain associated with Rheumatoid arthritis
Celecoxib Dose in Adults
-
A General Note about Celecoxib:
- Use the lowest possible dose
- Use for the shortest possible time
- cardiovascular disease patienrs should not take
- Avoid in patients with heart failure.
-
Use of Celecoxib in the treatment of Acute pain or primary dysmenorrhea:
- On day 1, take 400 mg as the first dose and then 200 mg more if necessary.
- Continue taking a 200 mg maintenance dose twice daily as necessary.
-
Use of Celecoxib in the treatment of Ankylosing spondylitis:
- 100 mg twice daily or 200 mg once daily.
- The dose may be increased to 400 mg per day after six weeks if required.
- If the drug is not effective after 6 weeks in a dose of 400 mg per day, alternate therapies may be tried.
-
Off label use as an alternative agent in the treatment of acute flare of Gouty arthritis:
- 200 mg two times a day for the usual duration of 5 - 7 days
- It should be initiated within 24 - 48 hours of flare onset.
- Two to three days following the onset of the resolution of symptoms, therapy should be stopped.
-
Use in the Treatment of Osteoarthritis:
- 200 mg once a day or
- 100 mg two times a day.
-
Use in the treatment of Rheumatoid arthritis:
- 100 - 200 mg two times a day.
Celecoxib Dose in Children
Dose in Juvenile idiopathic arthritis (JIA):
- Children older than 2 years and Adolescents weighing 10 - 25 kgs:
- 50 mg two times a day.
- weight of more than 25 kgs:
- 100 mg two times a day.
Pregnancy Risk Factor C if less than than 30 weeks gestation
Pregnancy Risk Factor D if more than 30 weeks gestation
- Celecoxib, as with other NSAIDs is associated nonteratogenic results, such as the prenatal closing of ductus Arteriosus, persistent pulmonary Hypertension of the newborn (PPH), oligohydramnios and renal dysfunction or failure.
- It should not be used in autoimmune rheumatic conditions.
- Studies have also linked it to infertility, miscarriages and other problems.
Celecoxib use duringBreastfeeding:
- Celecoxib can be found in breast milk in small amounts. It is compatible with breastfeeding.
- Patients taking anticoagulants, low platelets count or platelet dysfunction should be cautious.
Celecoxib Dose in Renal Disease:
- Mild to moderate renal impairment:
- The manufacturer does not recommend any dose adjustment, however, renal functions should be monitored.
- Severe renal impairment:
- Not recommended in severe renal disease.
- In addition, celecoxib should be discontinued in patients who develop renal dysfunction following its use and have a persistently abnormal or worsening renal dysfunction.
Celecoxib dose in Liver Disease:
-
Mild hepatic impairment (Child-Pugh class A):
- Dose adjustment is not necessary;
-
Moderate impairment (Child-Pugh class B):
- Reduce the dose by half.
-
Severe impairment (Child-Pugh class C):
- It is contraindicated in patients with severe liver disease.
-
Persistent or worsening liver function tests:
- Therapy should be discontinued.
Common Side Effects Of Celecoxib include:
-
Dermatologic:
- Acute generalized exanthematous pustulosis
- Exfoliative dermatitis
-
Gastrointestinal:
- Gastrointestinal perforation
- Gastrointestinal ulcer
- GI inflammation
- Intestinal perforation
-
Hypersensitivity:
- Anaphylaxis
-
Immunologic:
- DRESS syndrome
-
Respiratory:
- Local alveolar osteitis (post oral surgery patients)
Less Common Side Effects of Celecoxib include:
-
Cardiovascular:
- Peripheral edema
-
Gastrointestinal:
- Diarrhea
- Dyspepsia
- Abdominal pain
- Flatulence
- Gastroesophageal reflux disease
- Vomiting
-
Hepatic:
- Increased liver enzymes
-
Renal:
- Nephrolithiasis
-
Respiratory:
- Upper respiratory tract infection
- Sinusitis
- Pharyngitis
- Rhinitis
- Dyspnea
-
Miscellaneous:
- Accidental injury
Contraindication to Celecoxib include:
- Allergic reaction to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation
- Patients suffering from NSAID- or aspirin-induced allergies, asthma, or urticaria.
- CABG surgery is performed.
- The third trimester is when you can expect to have a baby
- Breastfeeding women
- Heart failure that is severe and not compensable
- Duodenal or active gastric ulcer
- Active gastrointestinal bleeding
- Inflammatory bowel disease
- Active hepatitis or decompensated liver disease
- Grave renal impairment, CrCl less than 30mL/minute
- Hyperkalemia
- Patients under 18 years old
Warnings and Precautions
- Anaphylactoid reactions
- Angioedema and anaphylactic reactions may occur in patients who are taking the aspirin-triad (Asthma/rhinitis and aspirin intolerance).
- Cardiovascular events [US Boxed Warning]
- The risk of cardiovascular events such as a stroke or myocardial infarction may increase if you use celecoxib and other NSAIDs.
- Patients with a history of cardiovascular disease or other risk factors are at greater risk.
- NSAIDs can also affect the response to ACE inhibitors or thiazide diuretics.
- It can cause fluid retention and sodium buildup. Patients with heart failure should avoid it.
- Gastrointestinal events: [US Boxed Warning]
- NSAIDs increase the risk of stomach ulcers and bleeding, which might result in perforation, which could be fatal.
- Individuals at higher risk include those who have had gastrointestinal bleeding, peptic ulcer disease, or who are old.
- Serious GI bleeding is more likely in patients who also use steroids, SSRIs, and anticoagulants.
- Patients at higher risk for GI bleeding are the elderly, smokers and alcoholics as well as patients with multiple comorbidities.
- Hematologic effects
- Anemia should be checked in patients receiving long-term therapy.
- It doesn't affect the platelet count nor the coagulation profile.
- Celecoxib at the appropriate doses does not inhibit platelet accumulation
- Reactions to skin:
- Celecoxib and other NSAIDs have been linked to significant skin side effects include exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis (TEN).
- If a rash occurs, it should be stopped immediately
- Allergy to sulfonamide (sulfa):
- Cross-sensitivity to sulfonamide antibiotics is a concern. Celecoxib should not be used by patients with severe allergic reactions to sulfonamide anti-biotics.
- Asthma
- Aspirin-sensitive asthma patients should be advised to avoid it.
- Coronary bypass surgery for coronary artery bypass graft: [US Boxed Warning]
- Celecoxib should not be used in conjunction with CABG (coronary bypass graft surgery). It may increase the risk for stroke and myocardial damage.
- Patients with Cytochrome P450 deficiency of Cytochrome 2C9 should be cautious.
- Hepatic impairment
- Individuals with moderate to severe hepatic impairment should use it with caution, and patients with severe liver illness should avoid it.
- Patients' liver function needs to be checked on a frequent basis.
- Renal impairment
- NSAIDs can cause a decrease in renal blood flow, which may lead to renal injury, or worsen a previously existing renal injury, especially in patients who have hypotension, heart disease, heart failure, and patients with hypotension.
- Long-term therapy can lead to pappillary necrosis.
Celecoxib: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy). |
|
5-Aminosalicylic Acid Derivatives | Nonsteroidal anti-inflammatory agents may increase the nephrotoxic effects of 5-Aminosalicylic acid derivatives. |
Ajmaline | Sulfonamides can increase the toxic/adverse effects of Ajmaline. Particularly, there may be an increase in the risk of cholestasis. |
Alcohol (Ethyl) | This combination may increase the toxic/adverse effects of Nonsteroidal Anti-Inflammatory Drugs. This combination may increase the risk of GI bleeding. |
Aliskiren | Aliskiren's antihypertensive effects may be diminished by nonsteroidal Anti-Inflammatory agents. Aliskiren's nephrotoxic effects may be augmented by nonsteroidal anti-inflammatory agents. Patients receiving aliskiren or any other nonsteroidal anti-inflammatory drug should be monitored regularly. Pre-existing or elderly patients are at higher risk for renal dysfunction. |
Aminoglycosides | Nonsteroidal anti-inflammatory agents may reduce the excretion Aminoglycosides. Only data available in infants who are premature. |
Aminolevulinic Acid Topical | Aminolevulinic Acid Topical's photosensitizing effects may be exacerbated by photosensitizing substances. |
Angiotensin II Receptor Blockers | Can intensify nonsteroidal anti-inflammatory drug's toxic/unfavorable effects. The combination can cause renal function to significantly decline. The therapeutic effects of angiotensin II receptor blockers may be lessened by nonsteroidal anti-inflammatory drugs. In addition to lowering glomerular filtration, combining these two drugs may even improve renal function. |
Angiotensin-Converting Enzyme Inhibitors | May make nonsteroidal anti-inflammatory drugs more toxic or harmful. The combination can cause renal function to significantly decline. Angiotensin-Converting Enzyme Inhibitors' antihypertensive effects may be lessened by nonsteroidal anti-inflammatory drugs. |
Anticoagulants | Anticoagulants' anticoagulant effects may be exacerbated by nonsteroidal anti-inflammatory drugs. |
ARIPiprazole | CYP2D6 inhibitors (Weak) may raise ARIPiprazole's serum levels. It's crucial to keep an eye out for any heightened pharmacologic effects of aripiprazole. Depending on the indication and concurrent medication, aripiprazole dosage modifications may be required. See the interaction monograph in its entirety for more details. |
Beta-Blockers | The antihypertensive effects of beta-blockers may be diminished by nonsteroidal anti-inflammatory drugs. The exceptions include metipranolol and levobunolol. |
Bisphosphonate Derivatives | Nonsteroidal anti-inflammatory agents may increase the toxic/adverse effects of Bisphosphonate derivatives. There is a greater risk of gastrointestinal bleeding and a higher risk of nephrotoxicity. |
Corticosteroids (Systemic) | May increase the toxic/adverse effects of Nonsteroidal AntiInflammatory Agents. (COX-2 Selective). |
Moderate CYP2C9 Inducers | Could lower the serum concentration of CYP2C9 substrates (High Risk with Inducers). |
Moderate CYP2C9 Inhibitors | Might decrease metabolism of CYP2C9 substrates (High Risk with Inhibitors). |
Dapsone (Topical) | May intensify the toxic/unfavorable effects of agents associated with methemoglobinemia. |
Deferasirox | Nonsteroidal Anti-Inflammatory Drugs (NSA) may intensify Deferasirox's hazardous or negative effects. Particularly, there may be a higher risk of GI bleeding or ulcers. |
Desmopressin | Nonsteroidal Anti-Inflammatory Medications (NSA) may intensify Desmopressin's hazardous or negative effects. |
Digoxin | Nonsteroidal anti-inflammatory drugs may raise the serum levels of digoxin. |
Drospirenone | The hyperkalemic effects of drospirenone may be increased by nonsteroidal anti-inflammatory drugs. |
Eplerenone |
Eplerenone's antihypertensive effects may be lessened by nonsteroidal anti-inflammatory drugs. Eplerenone's hyperkalemic effects may be amplified by non-steroidal anti-inflammatory drugs. |
Estrogen Derivatives | The thrombogenic effects of oestrogen derivatives may be enhanced by nonsteroidal anti-inflammatory drugs (COX-2 Selective). The serum levels of oestrogen derivatives may rise in response to COX-2 selective nonsteroidal anti-inflammatory drugs. |
Felbinac | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Haloperidol | Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the toxic/adverse effects of Haloperidol. This includes confusion and drowsiness. |
HydrALAZINE | HydrALAZINE's antihypertensive effects may be diminished by nonsteroidal anti-inflammatory agents. |
Local Anesthesia | Agents associated with methemoglobinemia may intensify the negative or toxic effects of local anaesthetics. Risk of methemoglobinemia could rise. |
Lumacaftor | May lower the serum concentrations of CYP2C9 substrates (High risk with inhibitors or inducers). Lumacaftor could increase serum concentrations of CYP2C9 substrates (High-Risk with Inhibitors and Inducers). |
Naftazone | May increase the antiplatelet effects of nonsteroidal anti-inflammatory agents. |
Nitric Oxide | May intensify the toxic/unfavorable effects of agents associated with methemoglobinemia. Methemoglobinemia risk may rise when these drugs are combined. Monitoring patients for symptoms like hypoxia and cyanosis is crucial when nitric oxide is coupled with other substances that can lead to methemoglobinemia. Do not use lidocaine or prilocaine. |
Perhexiline | Perhexiline serum concentration may be increased by CYP2D6 inhibitors (Weak). |
Porfimer | Photosensitizing agents may increase the photosensitizing effects of Porfimer. |
Potassium-Sparing Diuretics | Nonsteroidal Anti Inflammatory Agents can decrease the antihypertensive effects of Potassium–Sparing Diuretics. Nonsteroidal Anti Inflammatory Agents can increase the hyperkalemic effects of Potassium–Sparing Diuretics. |
PRALAtrexate | PRALATREXATE may be increased by nonsteroidal anti-inflammatory agents (NSAIDS). Specifically, NSAIDS can decrease renal excretion. Monitoring: Keep an eye out for elevated pralatrexate levels or toxicity if a NSAID is used in conjunction. Monitoring for decreased pralatrexate levels after discontinuation of NSAIDs is a good idea. |
Prilocaine | The toxic/unfavorable effects of Prilocaine may be exacerbated by Methemoglobinemia Related Agents. Methemoglobinemia risk can be raised when these drugs are combined. Keep an eye out for symptoms like hypoxia and cyanosis in patients when prilocaine is taken with other drugs that can result in methemoglobinemia. Infants receiving lidocaine or prilocaine shouldn't be administered lidocaine or prilocaine. |
Probenecid | Increases the levels of non-steroidal anti-inflammatory drugs in the serum. |
Prostaglandins Ophthalmic | Nonsteroidal Anti Inflammatory Agents can decrease the therapeutic effects of Prostaglandins Ophthalmic. Nonsteroidal Anti Inflammatory Agents can also increase the therapeutic effect of Prostaglandins Ophthalmic. |
Quinolones | Nonsteroidal Anti Inflammatory Agents can increase the neuroexcitatory or seizure-potentiating effects of Quinolones. Nonsteroidal Anti-Inflammatory agents may increase Quinolones' serum levels. |
Rifapentine | Could lower the serum concentration of CYP2C9 substrates (High Risk with Inducers). |
Selective Serotonin Reuptake inhibitors | Nonsteroidal Anti-Inflammatory Drugs (selective for COX-2) may have a stronger antiplatelet effect. Selective COX-2 non-steroidal anti-inflammatory drugs may lessen the therapeutic benefit of selective serotonin reuptake inhibitors. |
Sodium Nitrite | Methemoglobinemia Associated Agents can increase the toxic/adverse effect of Sodium Nitrite. Combinations of these agents could increase the chance of significant methemoglobinemia. |
Tacrolimus (Systemic) | Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the nephrotoxic effects of Tacrolimus. |
Thiazide and Thiazide -Like Diuretics | The nephrotoxic effects of nonsteroidal anti-inflammatory drugs may be more severe. Thiazide or Thiazide-Like Diuretics may have less therapeutic benefit when taken with nonsteroidal anti-inflammatory drugs. |
Tolperisone | Tolperisone's toxic/adverse effects may be exacerbated by nonsteroidal anti-inflammatory agents. Hypersensitivity reactions, in particular, may increase. The therapeutic effects of Nonsteroidal Anti-Inflammatory Drugs may be enhanced by Tolperisone. |
Tricyclic Antidepressants (Tertiary Amine). | May intensify nonsteroidal anti-inflammatory drug's antiplatelet effects (COX-2 Selective). |
Triflusal | NSAIDs (non-steroidal anti-inflammatory drugs) may reduce Triflusal's ability to bind to proteins. Particularly, NSAIDs can lessen protein binding to the active metabolite of triflusal. The protein binding of nonsteroidal anti-inflammatory drugs to triflusal may be reduced. |
Vancomycin | Vancomycin may be increased by nonsteroidal anti-inflammatory agents. |
Verteporfin | Verteporfin's photosensitizing effects may be exacerbated by photosensitizing substances. |
Vitamin K antagonists (eg warfarin) | The anticoagulant effects of vitamin K antagonists could be enhanced by nonsteroidal anti-inflammatory drugs that are COX-2 selective. Nonsteroidal Anti-Inflammatory Drugs, COX-2 Selective may elevate serum levels of Vitamin K Antagonists. |
Risk Factor D (Consider therapy modifications) |
|
Aspirin | Can increase the toxic/adverse effects of Nonsteroidal Anti-Inflammatory Drugs (COX-2 Selective). Management: It is not recommended to use aspirin in combination with cardioprotective doses. Concurrent use of low-dose aspirin and a COX-2 inhibitor with aspirin is allowed, but patients should be closely monitored for signs/symptoms such as GI ulceration/bleeding. |
Bile Acid Sequestrants | This may decrease the absorption rate of nonsteroidal anti-inflammatory agents. |
CycloSPORINE Systemic | CycloSPORINE Systemic may have a nephrotoxic effect due to nonsteroidal anti-inflammatory agents. CycloSPORINE Systemic may increase serum levels of Nonsteroidal Anti-Inflammatory agents. The serum concentration of CycloSPORINE Systemic may be increased by nonsteroidal anti-inflammatory agents. Management: Look for alternatives to nonsteroidal, anti-inflammatory drugs (NSAIDs). Monitor for signs of nephrotoxicity and elevated serum cyclosporine levels or systemic effects (eg hypertension) when NSAID therapy is combined. |
Dabrafenib | High risk of Inducers causing a decrease in serum CYP2C9 substrates. Management: If possible, seek alternatives to the CYP2C9 substrat. Concomitant therapy should be avoided if possible. Monitor the clinical effects of the substrate carefully (especially therapeutic effects). |
Enzalutamide | High risk of Inducers causing a decrease in serum concentrations of CYP2C9 substrates. Management: Avoid concurrent use of enzalutamide and CYP2C9 substrates with a narrow therapeutic index. You should exercise caution when using enzalutamide or any other CYP2C9 substrat. |
Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry) | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. There may be bleeding. Treatment: Avoid concurrent use of these agents. Concomitant use of these agents should be avoided. |
Lithium | The serum level of Lithium may be increased by nonsteroidal anti-inflammatory agents. |
Loop Diuretics | Loop Diuretics may have a less diuretic effect than nonsteroidal Anti-Inflammatory agents. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) may have a greater nephrotoxic effect than Loop Diuretics. Monitoring: Look out for signs of kidney injury and decreased therapeutic effects from loop diuretics when used in conjunction with an NSAID. Avoid concurrent use of NSAIDs in CHF and cirrhosis. It is not recommended to use bumetanide and indomethacin together. |
Methotrexate | The serum Methotrexate concentration may be increased by nonsteroidal anti-inflammatory agents. Management: If the patient is currently receiving high doses of Methotrexate, it is important to consider alternative anti-inflammatory therapies. |
MiFEPRIStone | Substantial potential for serum CYP2C9 substrates to increase as a result of inhibitors. Management: Maintain the lowest dose of CYP2C9 substrates and carefully monitor for negative side effects both during and after mifepristone treatment. |
Sincalide | Sincalide may be less effective if drugs that affect gallbladder function are taken. Management: Before Sincalide is used to stimulate the gallbladder, discontinue any drugs that affect gallbladder motility. |
Sodium Phosphates | Nonsteroidal Anti-Inflammatory Agents may have a greater nephrotoxic impact. In particular, acute phosphate neuropathy could be increased. Management: You can avoid this combination by temporarily stopping treatment with NSAIDs or looking for alternatives to oral sodium phosphate bowel prep. Maintain adequate hydration, and closely monitor your renal function if the combination is not possible. |
Tenofovir Products | The nephrotoxic effects of tenofovir products may be exacerbated by nonsteroidal anti-inflammatory drugs. Management: If at all possible, try for different combinations. A high dosage of any NSAID or the combination of tenofovir and another NSAID should be avoided. |
Risk Factor X (Avoid Combination) |
|
Acemetacin | Nonsteroidal anti-inflammatory medications (NSAIDs) may have a more negative/toxic effect. |
Aminolevulinic Acid Systemic | The photosensitizing effects of Aminolevulinic Acid Systemic may be enhanced by the use of photosensitizing agents. |
Dexibuprofen | Nonsteroidal Anti-Inflammatory Drugs (NSA) may increase the toxic/adverse effects of Dexibuprofen. |
Dexketoprofen | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Floctafenine | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Ketorolac, (Nasal). | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Ketorolac Systemic | Nonsteroidal anti-inflammatory medications (NSAIDs) may have a more negative/toxic effect. |
Macimorelin | Medications called Nonsteroidal Anti-Inflammatory Substances (NSA) may lessen Macimorelin's diagnostic potency. |
Mecamylamine | Sulfonamides may make mecamylamine more poisonous or harmful. |
Mifamurtide | Nonsteroidal anti-inflammatory agents (NSA) may reduce the therapeutic effects of Mifamurtide. |
Morniflumate | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Nonsteroidal Anti-Inflammatory Drugs | Increased use of nonsteroidal anti-inflammatory drugs may have hazardous or negative effects (COX-2 Selective). |
Nonsteroidal Anti-Inflammatory Agents COX-2 Selective | Compared to nonsteroidal anti-inflammatory drugs, nonsteroidal anti-inflammatory medicines (COX-2 Selective) may have a more negative/toxic effect. |
Omacetaxine | Omacetaxine's toxic/adverse effects may be exacerbated by nonsteroidal anti-inflammatory agents. In particular, bleeding-related events could be more common. Patients with a platelet count below 50,000/uL should not use omacetaxine and nonsteroidal anti-inflammatory drugs (NSAIDs). |
Pelubiprofen | Nonsteroidal anti-inflammatory medications (NSAIDs) may have a more negative/toxic effect. |
Phenylbutazone | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Talniflumate | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Tenoxicam | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Zaltoprofen | Nonsteroidal Anti-Inflammatory Drugs may have a greater adverse/toxic impact. |
Monitor:
- CBC
- Liver functions tests
- Renal function tests & Metabolic profile
- Observe for occult blood loss and dyspepsia
- Monitor response to treatment including pain, mobility, range of movements, grip strength, and features of inflammation
- Blood pressure at baseline and during treatment
- Observe for weight gain & edema
JIA: Monitor for development of abnormal coagulation tests with systemic onset JIA
How to Administer Celecoxib?
- You can either take celecoxib with or without food.
- Its contents can be dusted on applesauce, dumped onto a teaspoon of lukewarm or room temperature applesauce, and then immediately taken with water. It can also be consumed whole.
Mechanism of action of Celecoxib:
- It has antipyretic, anti-inflammatory, and analgesic effects.
Slowly, it isabsorbedIt is 97% bound with proteins.
It isMetabolizedThe liver converts inactive metabolites via CYP2c9
Thehalf-life eliminationThe average time it takes to get the drug into children and adolescents is six hours, while adults can take it for up to 11 hours.
TheTime to reach peakThe serum concentration takes 3 hours.
It isexcretedPrimarily via feces peak.
International brand names of Celecoxib:
- ACCEL-Celecoxib
- ACT Celecoxib
- AG-Celecoxib
- APO-Celecoxib
- Auro-Celecoxib
- BIO-Celecoxib
- CeleBREX
- GD-Celecoxib
- JAMP-Celecoxib
- Mar-Celecoxib
- MINT-Celecoxib
- MYLAN-Celecoxib
- PMS-Celecoxib
- Priva-Celecoxib
- RAN-Celecoxib
- RIVA-Celecox
- SANDOZ Celecoxib
- SDZ Celecoxib
- TEVA-Celecoxib
- Acicox
- Aclexa
- Algoxib
- Artilog
- Artose
- Arythrex
- Aubrex
- Brexen
- Caditar
- Cecox
- Celbexx
- Celbric
- Celcox
- Celcoxx
- Cele V
- Celebex
- Celebone
- Celebra
- Celebrex
- Celecox
- Celecsil
- Celenta
- Celexib
- Celexil
- Celib
- Celofen
- Celoxib
- Celxib
- Celzib
- Cerebrex
- Colcibid
- Colcibra
- Cox-2
- Coxib
- Coxileb
- Coxoral
- Coxzan
- Eliflam
- Eurocox
- Ezy
- Flamar
- Flamex
- Flaxel
- Flogoxib
- Geocoxib
- Icox
- Keltrex
- Letabex
- Lexfin
- Mecelxib
- Mibecerex
- Miodar
- Nacoxib
- Onsenal
- Painex
- Rancelex
- Ranselex
- Relexa
- Revcox
- Roxib
- Selexa
- Stadloric
- Stadloric 200
- Unicelib
- Valdyne
- Zecroxil
- Zobrex
- Zycel
Celecoxib brands in Pakistan:
Celecoxib [Tabs 100 Mg] |
|
Artocel | Honig Pharmaceuticals Laboratories |
Celconid | Caraway Pharmaceuticals |
Ecoloxib | Navegal Laboratories |
Medicoxib | Mediceena Pharma (Pvt) Ltd. |
Osteoxib | Zesion Pharmaceutical (Pvt) Ltd |
Sancel | Robins Pharmaceutical Industries |
Sefecox | Pharmevo (Pvt) Ltd. |
Seleco | Wilshire Laboratories (Pvt) Ltd. |
Shexib | Everest Pharmaceuticals |
Shexib | Everest Pharmaceuticals |
Celecoxib [Tabs 200 Mg] |
|
Ecoloxib | Navegal Laboratories |
Emphatic | Hygeia Pharmaceuticals |
Osteoxib | Zesion Pharmaceutical (Pvt) Ltd |
Postaglin | Medicraft Pharmaceuticals (Pvt) Ltd. |
Sancel | Robins Pharmaceutical Industries |
Sefecox | Pharmevo (Pvt) Ltd. |
Seleco | Wilshire Laboratories (Pvt) Ltd. |
Shexib | Everest Pharmaceuticals |
Shexib | Everest Pharmaceuticals |
Celecoxib [Caps 100 Mg] |
|
Articoxib | Nabiqasim Industries (Pvt) Ltd. |
Biox | Vega Pharmaceuticals Ltd. |
Bixo | Vega Pharmaceuticals Ltd. |
Bloxib | Bloom Pharmaceuticals (Pvt) Ltd. |
Celart | Hilton Pharma (Pvt) Limited |
Celbexx | Getz Pharma Pakistan (Pvt) Ltd. |
Cele | Tg Pharma |
Celecoxx | Semos Pharmaceuticals (Pvt) Ltd. |
Celetab | Indus Pharma (Pvt) Ltd. |
Celmax | Max Pharmaceuticals |
Celoxib | The Schazoo Laboratories Ltd. |
Celzib | Well & Well Pharma (Pvt) Ltd |
Ecoxib | Epoch Pharmaceutical |
Emphatic | Hygeia Pharmaceuticals |
Gauld | Karachi Chemical Industries |
Geocoxib | Geofman Pharmaceuticals |
Gilbex | Genome Pharmaceuticals (Pvt) Ltd |
Lecoxib | Paramount Pharmaceuticals |
Moveryl | Sami Pharmaceuticals (Pvt) Ltd. |
Nuzib | Bosch Pharmaceuticals (Pvt) Ltd. |
Osteocox | Friends Pharma (Pvt) Ltd |
Postaglin | Medicraft Pharmaceuticals (Pvt) Ltd. |
Rheuoxib | Highnoon Laboratories Ltd. |
Rival | Kurative Pak (Pvt) Ltd |
Seloxx | Efroze Chemical Industries (Pvt) Ltd. |
Unicoxib | Tg Pharma |
Celecoxib [Caps 200 Mg] |
|
Articoxib | Nabiqasim Industries (Pvt) Ltd. |
Artiflex | Standpharm Pakistan (Pvt) Ltd. |
Biox | Vega Pharmaceuticals Ltd. |
Bixo | Vega Pharmaceuticals Ltd. |
Bloxib | Bloom Pharmaceuticals (Pvt) Ltd. |
Celart | Hilton Pharma (Pvt) Limited |
Celbexx | Getz Pharma Pakistan (Pvt) Ltd. |
Cele | Tg Pharma |
Celecomed | Mediate Pharmaceuticals (Pvt) Ltd |
Celecoxx | Semos Pharmaceuticals (Pvt) Ltd. |
Celetab | Indus Pharma (Pvt) Ltd. |
Celewin | Wns Field Pharmaceuticals |
Celicob | Mass Pharma (Private) Limited |
Celmatic | Aptcure Private Limited |
Celmax | Max Pharmaceuticals |
Celoxib | The Schazoo Laboratories Ltd. |
Celstar | Pharmatec Pakistan (Pvt) Ltd. |
Celtex | Panacea Pharmaceuticals |
Celtic | Genome Pharmaceuticals (Pvt) Ltd |
Celzib | Well & Well Pharma (Pvt) Ltd |
Cobix | Eg Pharmaceuticals |
Cobix | Eg Pharmaceuticals |
Coxban | Rakaposhi Pharmaceutical (Pvt) Ltd. |
Coxgen | Genome Pharmaceuticals (Pvt) Ltd |
Dorsiflex | Consolidated Chemical Laboratories (Pvt) Ltd. |
Dorsiflex | Consolidated Chemical Laboratories (Pvt) Ltd. |
Ecoxib | Epoch Pharmaceutical |
Gauld | Karachi Chemical Industries |
Geocoxib | Geofman Pharmaceuticals |
Gilbex | Genome Pharmaceuticals (Pvt) Ltd |
Lecoxib | Paramount Pharmaceuticals |
Markzib | Welmark Pharmaceuticals |
Moveryl | Sami Pharmaceuticals (Pvt) Ltd. |
Nuzib | Bosch Pharmaceuticals (Pvt) Ltd. |
Rheuoxib | Highnoon Laboratories Ltd. |
Seloxx | Efroze Chemical Industries (Pvt) Ltd. |
Selxib | Fynk Pharmaceuticals |
Sixib | Siam Pharmaceuticals |
Thiocid | Rogen Pharmaceuticals |
Unicoxib | Tg Pharma |
Wecox | Wise Pharmaceuticals (Pvt) Ltd |